<code id='90258BAAF4'></code><style id='90258BAAF4'></style>
    • <acronym id='90258BAAF4'></acronym>
      <center id='90258BAAF4'><center id='90258BAAF4'><tfoot id='90258BAAF4'></tfoot></center><abbr id='90258BAAF4'><dir id='90258BAAF4'><tfoot id='90258BAAF4'></tfoot><noframes id='90258BAAF4'>

    • <optgroup id='90258BAAF4'><strike id='90258BAAF4'><sup id='90258BAAF4'></sup></strike><code id='90258BAAF4'></code></optgroup>
        1. <b id='90258BAAF4'><label id='90258BAAF4'><select id='90258BAAF4'><dt id='90258BAAF4'><span id='90258BAAF4'></span></dt></select></label></b><u id='90258BAAF4'></u>
          <i id='90258BAAF4'><strike id='90258BAAF4'><tt id='90258BAAF4'><pre id='90258BAAF4'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:2621
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Continuity nursing helped my family in our darkest PICU moments
          Continuity nursing helped my family in our darkest PICU moments

          EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

          read more
          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

          ChristineKao/STATTheFoodandDrugAdministration’sapprovalonFridayoftwogenetherapiesforsicklecelldiseas

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Roche drug slashes death risk in early

          Roche'sboothatthe2023ESMOconference.AndrewJoseph/STATMADRID—ARochedrugloweredtheriskofrecurrenceorde